Stemcells to Present at New York Stem Cell Summit
Product News Feb 24, 2011
StemCells, Inc. has announced that Martin McGlynn, President and CEO, and Stephen Huhn, M.D., Vice President and Head of CNS Program, have each been invited to speak at the 6th Annual New York Stem Cell Summit to be held March 1 at Bridgewaters in New York City.
This year’s Summit will feature a panel discussion on stem cell approaches to spinal cord injury, including the Company’s recently authorized Phase I/II clinical trial of its HuCNS-SC® cells (purified human neural stem cells) in chronic spinal cord injury, which will be conducted in Switzerland.
Mr. McGlynn will present a corporate overview at 2:35 p.m. Eastern Time. Immediately following, Dr. Huhn will participate in the spinal cord injury panel, scheduled from 2:47 to 3:30 p.m. Eastern Time, during which he will present the preclinical basis for the use of HuCNS-SC cells in patients living with paralysis along with the innovative design of the Company’s Phase I/II trial, which will progressively enroll patients based upon the severity of injury.
This trial is the first to evaluate neural stem cell transplantation as a potential treatment for spinal cord injury, and is expected to begin accruing patients next month.
The New York Stem Cell Summit brings together stem cell company executives, scientists, investors and physicians to explore investment opportunities in the stem cell marketplace, groundbreaking stem cell products, and the growing market potential for the industry.
The one-day event is organized by RRY Publications, and features presentations by leaders in stem cell research, innovation and industry. More information on the event can be found at http://www.stemcellsummit.com.